Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892132 · ClinicalTrials.gov registry record · NA
Evaluation of a Supervised Clinical Feeding Intervention
A NA study, sponsored by Boston Children's Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 320
- Enrollment target
NCT06892132: Clinical Trial NA study, sponsored by Boston Children's Hospital.
NCT06892132 is a NA study that has not yet begun recruiting, run by Boston Children's Hospital. The registered enrollment target is 320 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892132, a NA study, has not yet begun recruiting, sponsored by Boston Children's Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 320 participants
- Enrollment target
Study Summary
Peanut allergies affect approximately 2.5% of children; are associated with significant mortality, morbidity, and economic costs; and often lead to persistent peanut allergies in adulthood. We now know however that early introduction of peanut products to infants prior to age 7 months and maintained in the diet regularly significantly reduces the rate of peanut allergies. Unfortunately, recent research shows that even when parents know the recommendations to feed peanut products early and often, \<50% of parents report introducing peanuts by age 9 months, \<45% are offering peanut products several times a week, and \<20% are offering the recommended 2 teaspoons at each feeding. Many parents cite a fear of reactions or a lack of knowledge on how to safely feed peanut products at this age. While there are recommendations to offer the first feeding in clinic this has not been widely implemented in general pediatrics clinics and we have no research to say this is an effective way to increase peanut consumption at home. This research is being conducted to assess the effectiveness of a supervised peanut feeding clinic in a pediatric office to increase rate of guideline recommended peanut consumption in infants by 9 months of age.
Primary Outcome
Percentage of families who have introduced peanut products at home in 2 groups.
Interventions
- OTHER Handout
- OTHER Supervised feeding intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What is known before NCT06892132 opens enrollment
NCT06892132 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Handout is the first listed.
NCT06892132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06892132 about?
NCT06892132 is a clinical study titled "Evaluation of a Supervised Clinical Feeding Intervention". Peanut allergies affect approximately 2.5% of children; are associated with significant mortality, morbidity, and economic costs; and often lead to persistent peanut allergies in adulthood. We now know however that early introduction of peanut products to infants prior to age 7 months and maintained...
What is the current status of trial NCT06892132?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 320 participants. The study started on 2025-05-01. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT06892132?
The interventions under investigation include: Handout (OTHER), Supervised feeding intervention (OTHER).
Who is sponsoring clinical trial NCT06892132?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06892132's enrollment target sits among peer trials
320 315th of 2000 higher than 1,680 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI